SCHEMBL18890609

SCHEMBL18890609

COc1ccc2nc(-c3ccc(C)o3)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.58
TP53 P04637 5/20 0.58
ALDH1A1 P00352 4/20 0.58
HPGD P15428 4/20 0.58
RAB9A P51151 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
KDM4E B2RXH2 2/20 0.58
TSHR P16473 2/20 0.58
HSD17B10 Q99714 2/20 0.58
NFKB1 P19838 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
MEN1 O00255 3/20 0.56
POLB P06746 3/20 0.56
KMT2A Q03164 3/20 0.56
PKM P14618 2/20 0.56
LMNA P02545 1/20 0.56
PDPK1 O15530 1/20 0.54
USP2 O75604 1/20 0.54
RUNX1 Q01196 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18890607 0.89 AMY1A (0.46) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL18890545 0.82 ALDH1A1 (0.58) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL20982659 0.77 NPC1 (0.85) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL7037076 0.77 CHEK2 (0.65) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL18890639 0.76 MMP2 (0.58) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL18906383 0.76 ALDH1A1 (0.55) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL18890560 0.75 RHEB (0.51) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL3125413 0.75 NPC1 (0.75) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL29439014 0.74 KDM4E (0.61) NPC1TP53ALDH1A1HPGDRAB9A
SCHEMBL4371528 0.74 KDM4E (0.61) NPC1TP53ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152245-A1 BENZIMIDAZOLE COMPOUNDS AND THEIR APPLICATION IN CARDIOVASCULAR DISEASES NATIONAL TAIWAN UNIVERSITY (TW) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152245-A1 BENZIMIDAZOLE COMPOUNDS AND THEIR APPLICATION IN CARDIOVASCULAR DISEASES TNNI3, PDGFRA, PDGFRB NPC1 2699/4885TP53 4400/4885ALDH1A1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.